Corbus Pharmaceuticals Holdings Inc CRBP.OQ CRBP.O is expected to show a rise in quarterly revenue when it reports results on March 9 (estimated) for the period ending December 31 2025
The Norwood Massachusetts-based company is expected to report revenue of $1.667 million, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Corbus Pharmaceuticals Holdings Inc is for a loss of $1.58 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Corbus Pharmaceuticals Holdings Inc is $39.00, about 386.3% above its last closing price of $8.02
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -1.53 | -1.71 | -1.90 | Missed | -11.3 |
Jun. 30 2025 | -1.39 | -1.51 | -1.44 | Beat | 4.8 |
Mar. 31 2025 | -1.25 | -1.28 | -1.39 | Missed | -8.6 |
Dec. 31 2024 | -1.26 | -1.27 | -0.78 | Beat | 38.4 |
Sep. 30 2024 | -0.95 | -0.95 | -1.15 | Missed | -20.8 |
Jun. 30 2024 | -1.16 | -1.19 | -0.90 | Beat | 24.2 |
Mar. 31 2024 | -1.09 | -1.09 | -0.83 | Beat | 23.9 |
Dec. 31 2023 | -2.22 | -2.36 | -1.81 | Beat | 23.3 |
This summary was machine generated March 6 at 12:40 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments